Safety, biodistribution and viral shedding of oncolytic vaccinia virus TG6002 administered intravenously in healthy beagle dogs

Oncolytic virotherapy is an emerging strategy that uses replication-competent viruses to kill tumor cells. We have reported the oncolytic effects of TG6002, a recombinant oncolytic vaccinia virus, in preclinical human xenograft models and canine tumor explants. To assess the safety, biodistribution...

Descripción completa

Detalles Bibliográficos
Autores principales: Béguin, Jérémy, Gantzer, Murielle, Farine, Isabelle, Foloppe, Johann, Klonjkowski, Bernard, Maurey, Christelle, Quéméneur, Éric, Erbs, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7838210/
https://www.ncbi.nlm.nih.gov/pubmed/33500518
http://dx.doi.org/10.1038/s41598-021-81831-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7838210/
https://www.ncbi.nlm.nih.gov/pubmed/33500518
http://dx.doi.org/10.1038/s41598-021-81831-2

Ejemplares similares